Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
STU:2TZ's ROE % is ranked better than 92.43% of 938
companies
in the Drug Manufacturers industry
Industry Median: 6.02
vs STU:2TZ: 26.83
Tianjin Pharmaceutical Da Ren Tang Group (STU:2TZ) ROE % Explanation
ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.
The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:
Note:
The net income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net Income is used.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.
Tianjin Pharmaceutical Da Ren Tang Group ROE % Related Terms
Tianjin Pharmaceutical Da Ren Tang Group ROE % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tianjin Pharmaceutical Da Ren Tang Group ROE % Chart
Tianjin Pharmaceutical Da Ren Tang Group Annual Data
For the Drug Manufacturers - Specialty & Generic subindustry, Tianjin Pharmaceutical Da Ren Tang Group's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Tianjin Pharmaceutical Da Ren Tang Group ROE % vs Drug Manufacturers Industry
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
ROE % is displayed in the 30-year financial page.
Tianjin Pharmaceutical Da Ren Tang Group (STU:2TZ) has a ROE % of 23.58% as of Mar. 2026. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Tianjin Pharmaceutical Da Ren Tang Group and its competitors. This is 90% above median its historical median of 12.39. Over the past decade, Tianjin Pharmaceutical Da Ren Tang Group's ROE % has ranged from 10.45 to 30.87. According to the industry distribution chart, Tianjin Pharmaceutical Da Ren Tang Group ranks #71 out of 938 companies in the Drug Manufacturers industry, placing it in the top 7.6%.
Is Tianjin Pharmaceutical Da Ren Tang Group's ROE % too high?
Tianjin Pharmaceutical Da Ren Tang Group's current ROE % of 23.58% is 90% above median its 10-year median of 12.39. Over the past 10 years, this metric has ranged from a low of 10.45 to a high of 30.87. The Drug Manufacturers industry median ROE % is 6.02. Tianjin Pharmaceutical Da Ren Tang Group's value of 23.58% is 291.7% above this industry median. Based on the distribution chart, Tianjin Pharmaceutical Da Ren Tang Group ranks #71 out of 938 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Tianjin Pharmaceutical Da Ren Tang Group has a GF Score™ of 72/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Tianjin Pharmaceutical Da Ren Tang Group's ROE % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Tianjin Pharmaceutical Da Ren Tang Group ranks #71 out of 938 companies for ROE %. This places Tianjin Pharmaceutical Da Ren Tang Group in the top 8% of its industry — outperforming the majority of peers. The industry median ROE % is 6.02. Tianjin Pharmaceutical Da Ren Tang Group's value of 23.58% is 291.7% above this benchmark. Historically, Tianjin Pharmaceutical Da Ren Tang Group's own ROE % has ranged from 10.45 to 30.87 over the past decade. While the company's 10-year median is 12.39 vs. the industry median of 6.02, Tianjin Pharmaceutical Da Ren Tang Group has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Drug Manufacturers company?
The median ROE % among Drug Manufacturers companies is 6.02, based on 938 companies in the industry. Companies in the top quartile (top 25%) have a ROE % significantly above this median, while those in the bottom quartile fall well below. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Tianjin Pharmaceutical Da Ren Tang Group's current ROE % of 23.58% is 291.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Tianjin Pharmaceutical Da Ren Tang Group and its competitors. For the Drug Manufacturers industry, the median ROE % is 6.02 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Tianjin Pharmaceutical Da Ren Tang Group's current ROE % is 23.58%, which is 90% above median its own 10-year median of 12.39. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tianjin Pharmaceutical Da Ren Tang Group stock overvalued right now?
Based on GuruFocus' analysis, Tianjin Pharmaceutical Da Ren Tang Group (STU:2TZ) is currently considered Significantly Overvalued. The stock's GF Value™ is €1.64, compared to a current price of €2.44 — trading 48.8% above its estimated fair value. The current ROE % is 23.58%, which is 90% above median its 10-year median of 12.39 and 291.7% above the Drug Manufacturers industry median of 6.02. Tianjin Pharmaceutical Da Ren Tang Group's overall GF Score™ is 72/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For Tianjin Pharmaceutical Da Ren Tang Group (STU:2TZ), the current ROE % is 23.58% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Tianjin Pharmaceutical Da Ren Tang Group (STU:2TZ) Overvalued in 2026?
Based on GuruFocus' analysis, Tianjin Pharmaceutical Da Ren Tang Group stock appears to be overvalued.
The current stock price of €2.44 is trading 48.8% above its estimated GF Value™ of €1.64.
GuruFocus considers Tianjin Pharmaceutical Da Ren Tang Group to be Significantly Overvalued.
Key valuation signals for STU:2TZ:
ROE %: 23.58% (90% above median its 10-year median of 12.39)
GF Value™: €1.64 vs. price of €2.44 (48.8% above fair value)
Industry Position: 291.7% above the Drug Manufacturers median (#71 of 938)
No single metric tells the full story. See the STU:2TZ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Tianjin Pharmaceutical Da Ren Tang Group Business Description
Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd is a pharmaceutical manufacturing company. The company is engaged in the production and sale of traditional Chinese medicine, Western medicine, healthcare products, and investment holding. It operates in two segments, namely the Chinese Medicine segment and the Western Medicine segment. The Chinese Medicine segment manufactures Chinese pharmaceutical products under brands owned by the group. The Western Medicine segment manufactures Western pharmaceutical products through cooperation with foreign companies. The company earns the majority of its revenue from the sale of Chinese medicine.
72GF Score
Get the complete analysis for STU:2TZ
ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:2TZ has been successfully added to your 
